Details:
Lipidor AB has penned an agreement with Cadila Pharmaceuticals to conduct a Phase III study for Lipidor’s drug candidate AKP-02. AKP-02 is an antipsoriasis medicine that combines the active substances calcipotriol and betamethasone with Lipidor’s spray-based AKVANO technology.
Lead Product(s): Calcipotriol,Betamethasone
Therapeutic Area: Dermatology Product Name: AKP-02
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Lipidor AB
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 07, 2020
Details:
Sun Pharma has been granted a worldwide licence for the development and commercialization of SCD-044, which is being evaluated as a potential oral treatment for atopic dermatitis, psoriasis and other auto-immune disorders. SCD-044 is entering phase 2 clinical trials.
Lead Product(s): SCD-044
Therapeutic Area: Dermatology Product Name: SCD-044
Highest Development Status: Phase II Product Type: Undisclosed
Partner/Sponsor/Collaborator: Sun Pharmaceutical Industries Limited
Deal Size: $145.0 million Upfront Cash: $20.0 million
Deal Type: Licensing Agreement May 29, 2020
Details:
The initiation of this phase II study represents a significant milestone for Aurigene, as it marks the first program which Aurigene has led from the bench side to the clinic all by itself.
Lead Product(s): AUR101
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 18, 2020